These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22681783)

  • 1. Model uncertainty and model averaging in the estimation of infectious doses for microbial pathogens.
    Moon H; Kim SB; Chen JJ; George NI; Kodell RL
    Risk Anal; 2013 Feb; 33(2):220-31. PubMed ID: 22681783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing the theoretical foundations of the exponential and beta-Poisson dose-response models to quantify parameter uncertainty using Markov Chain Monte Carlo.
    Schmidt PJ; Pintar KD; Fazil AM; Topp E
    Risk Anal; 2013 Sep; 33(9):1677-93. PubMed ID: 23311599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential uncertainty reduction in model-averaged benchmark dose estimates informed by an additional dose study.
    Shao K; Small MJ
    Risk Anal; 2011 Oct; 31(10):1561-75. PubMed ID: 21388425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of model-averaged BMDLs: a study of model averaging in dichotomous response risk estimation.
    Wheeler MW; Bailer AJ
    Risk Anal; 2007 Jun; 27(3):659-70. PubMed ID: 17640214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model averaging in microbial risk assessment using fractional polynomials.
    Namata H; Aerts M; Faes C; Teunis P
    Risk Anal; 2008 Aug; 28(4):891-905. PubMed ID: 18564995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
    Zhu Y; Wang T; Jelsovsky JZ
    Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model averaging using the Kullback information criterion in estimating effective doses for microbial infection and illness.
    Moon H; Kim HJ; Chen JJ; Kodell RL
    Risk Anal; 2005 Oct; 25(5):1147-59. PubMed ID: 16297221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A diversity index for model space selection in the estimation of benchmark and infectious doses via model averaging.
    Kim SB; Kodell RL; Moon H
    Risk Anal; 2014 Mar; 34(3):453-64. PubMed ID: 23980524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the uncertainty in QUANTEC's dose-response relation of lung and spinal cord with a bootstrap analysis.
    Wedenberg M
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):795-801. PubMed ID: 23953634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of variability and uncertainty for censored data sets and application to air toxic emission factors.
    Zhao Y; Frey HC
    Risk Anal; 2004 Aug; 24(4):1019-34. PubMed ID: 15357825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Monte Carlo maximum likelihood method for estimating uncertainty arising from shared errors in exposures in epidemiological studies of nuclear workers.
    Stayner L; Vrijheid M; Cardis E; Stram DO; Deltour I; Gilbert SJ; Howe G
    Radiat Res; 2007 Dec; 168(6):757-63. PubMed ID: 18088178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian dose-response analysis for epidemiological studies with complex uncertainty in dose estimation.
    Kwon D; Hoffman FO; Moroz BE; Simon SL
    Stat Med; 2016 Feb; 35(3):399-423. PubMed ID: 26365692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model Uncertainty and Bayesian Model Averaged Benchmark Dose Estimation for Continuous Data.
    Shao K; Gift JS
    Risk Anal; 2014 Jan; 34(1):101-20. PubMed ID: 23758102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating model uncertainties along with data uncertainties in microbial risk assessment.
    Kang SH; Kodell RL; Chen JJ
    Regul Toxicol Pharmacol; 2000 Aug; 32(1):68-72. PubMed ID: 11029270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proof of concept and dose estimation with binary responses under model uncertainty.
    Klingenberg B
    Stat Med; 2009 Jan; 28(2):274-92. PubMed ID: 19012269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monotonic Bayesian semiparametric benchmark dose analysis.
    Wheeler M; Bailer AJ
    Risk Anal; 2012 Jul; 32(7):1207-18. PubMed ID: 22385024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards quantitative uncertainty assessment for cancer risks: central estimates and probability distributions of risk in dose-response modeling.
    Kopylev L; Chen C; White P
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):203-7. PubMed ID: 17905499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U.S. Environmental Protection Agency radiogenic risk projections: uncertainty analysis.
    Pawel DJ
    Health Phys; 2013 Jan; 104(1):26-40. PubMed ID: 23192084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian population analysis of a washin-washout physiologically based pharmacokinetic model for acetone.
    Mörk AK; Jonsson F; Johanson G
    Toxicol Appl Pharmacol; 2009 Nov; 240(3):423-32. PubMed ID: 19660484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling aggregate exposures to glycol ethers from use of commercial floor products.
    Koontz M; Price P; Hamilton J; Daggett D; Sielken R; Bretzlaff R; Tyler T
    Int J Toxicol; 2006; 25(2):95-107. PubMed ID: 16597548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.